PYPD

NASDAQ

PolyPid Ltd.

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2020

$4.61-0.06 (-1.28%)

News25/Ratings6

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product includes D-PLEX100, which is in Phase 3 clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Price$4.61-0.01 (-0.22%)

07:30 PM07:45 PM

News · 26 weeks33-75%

2025-11-022026-04-26

Mix2290d

Insider11(50%)
Other6(27%)
SEC Filings3(14%)
Earnings2(9%)

Latest news

25 items

12dPR
PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026
PETACH TIKVA, Israel, April 13, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that the Company will present new pharmacokinetic data from the Phase 3 SHIELD II trial evaluating D-PLEX₁₀₀ at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global 2026 (formerly known as ECCMID), the world's leading congress for clinical microbiology and infectious diseases, taking place on April 17-21, 2026, in Munich, Germany. The abstract titled "Pharmacokinetics of l
19dINSIDER
SEC Form 3 filed by new insider Jacobovitz Yitzchak Shlomo
3 - PolyPid Ltd. (0001611842) (Issuer)
19dINSIDER
SEC Form 3 filed by new insider Stein Robert Benjamin
3 - PolyPid Ltd. (0001611842) (Issuer)
25dSEC
SEC Form 6-K filed by PolyPid Ltd.
6-K - PolyPid Ltd. (0001611842) (Filer)
25dPR
PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA
PolyPid Submits First Modules as Part of Rolling NDA Review; Completion expected in Second Quarter of 2026 U.S. Commercialization Partnership Negotiations on Track PETACH TIKVA, Israel, March 31, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that it has initiated a New Drug Application ("NDA") submission to the U.S. Food and Drug Administration (the "FDA") for D-PLEX₁₀₀ for the prevention of surgical site infections ("SSIs") in patients undergoing colorectal surgery. The NDA is being submitted
30dINSIDER
SEC Form 3 filed by new insider Warshavsky Ori
3 - PolyPid Ltd. (0001611842) (Issuer)
30dINSIDER
SEC Form 3 filed by new insider Dror-Darwish Nir
3 - PolyPid Ltd. (0001611842) (Issuer)
33dINSIDER
SEC Form 3 filed by new insider Missulawin Jonathan
3 - PolyPid Ltd. (0001611842) (Issuer)
33dINSIDER
SEC Form 3 filed by new insider Barenholz Yechezkel
3 - PolyPid Ltd. (0001611842) (Issuer)
33dINSIDER
SEC Form 3 filed by new insider Benamram Joseph
3 - PolyPid Ltd. (0001611842) (Issuer)
38dINSIDER
SEC Form 3 filed by new insider Story Brooke
3 - PolyPid Ltd. (0001611842) (Issuer)
38dINSIDER
SEC Form 3 filed by new insider Krinsky Itzhak
3 - PolyPid Ltd. (0001611842) (Issuer)
38dINSIDER
SEC Form 3 filed by new insider Akselbrad Dikla Czaczkes
3 - PolyPid Ltd. (0001611842) (Issuer)
38dINSIDER
SEC Form 3 filed by new insider Hazan Dalit Fellous
3 - PolyPid Ltd. (0001611842) (Issuer)
39dPR
PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀'s New Drug Application
FDA Grants $4.3 Million Small Business Waiver, Enabling Focus on Commercialization Preparations Company On Track to Initiate NDA Submission by the End of this Month PETACH TIKVA, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that the U.S. Food and Drug Administration (FDA) has granted a small business waiver of the Prescription Drug User Fee Act (PDUFA) fee of approximately $4.3 million for the New Drug Application (NDA) for D-PLEX₁₀₀, the Company's lead product candidate for th
59dSEC
SEC Form 20-F filed by PolyPid Ltd.
20-F - PolyPid Ltd. (0001611842) (Filer)
59dPR
PolyPid Announces Participation in Upcoming Investor Conferences
PETACH TIKVA, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that senior management will participate in two upcoming investor conferences taking place during March 2026. Citizens 2026 Life Sciences Conference Date: March 10, 2026 at 1:40 pm ETLocation: Eden Roc Miami Beach, Miami Beach, FLFormat: Fireside chatWebcast Signup: https://event.summitcast.com/view/BuMiPNPtyHKimMF6k4AFMd/bygPbooQTs4VTXiUdoDYrb Investors who wish to meet with PolyPid management should contact their Citiz
73dSEC
SEC Form 6-K filed by PolyPid Ltd.
6-K - PolyPid Ltd. (0001611842) (Filer)
73dPR
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
The Company is in Advanced Stages of Commercial U.S. Partnership Discussions for D-PLEX₁₀₀ Positive FDA Pre-NDA Feedback Supports Rolling NDA Review; Submission Expected to Begin by the End of the First Quarter of 2026 Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Feb. 11, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today provided a corporate update and reported financial results for the three months and full year ended December 31, 2025. Recent Corporate Highlights: Advancing Towa
80dSEC
SEC Form 6-K filed by PolyPid Ltd.
6-K - PolyPid Ltd. (0001611842) (Filer)
85dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by PolyPid Ltd.
SCHEDULE 13G/A - PolyPid Ltd. (0001611842) (Subject)
87dPR
PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026
PETACH TIKVA, Israel, Jan. 28, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter 2025 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 11, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question
115dSEC
SEC Form 6-K filed by PolyPid Ltd.
6-K - PolyPid Ltd. (0001611842) (Filer)
130dSEC
SEC Form 6-K filed by PolyPid Ltd.
6-K - PolyPid Ltd. (0001611842) (Filer)
130dPR
PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors
PETACH TIKVA, Israel, Dec. 16, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Brooke Story as Chairman of the Board of Directors, effective as of December 11, 2025. "Brooke's appointment marks an exciting and pivotal moment for PolyPid," said Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid. "Her global expertise in the surgical market, specifically in infection prevention and advanced surgical solutions, combined with her extensive experience leading corporate strategy and corporate development transactions, will be instrumental in transfor